A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL (NCT06854653)
An Open-Label, Phase 2 Study of PTX-100 Monotherapy in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL). PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles, then 21 day cycle thereafter. Subjects will be treated or followed up, if subjects discontinue treatment, for up to 18 months.
Who can join: Review the eligibility criteria below.
Location: City of Hope Comprehensive Cancer Cente — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- City of Hope Comprehensive Cancer Cente — Duarte, California
- University of California Irvine — Irvine, California
- Yale Cancer Center — New Haven, Connecticut
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Rochester Skin Lymphoma Medical Group. PLLC — Rochester, New York
- Virginia Commonwealth University Massey Comprehensive Cancer Cente — Richmond, Virginia
- Westmead Hospital — Westmead, New South Wales
- Epworth Healthcare — Melbourne, Victoria
- Linear Clinical Research — Nedlands, Western Australia
- CHU de Bordeaux - Hopital Saint André — Bordeaux, Bordeaux
- Hopital Lyon Sud — Lyon, Pierre-Benite
- Hopital Saint Louis — Paris, Île-de-France Region
- IRCCS Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi — Bologna, Bologna
- Universita degli Studi Di Brescia-Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia — Brescia, Brescia
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele (HSR) (Istituto Scientifico Universitario San Raffaele) — Milan, Milano
📞 Contact the Study Coordinator
Phone: +61 3 9692 7222
Email: upaly@ptxtherapeutics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in CTCL
- StrataCTX® as a Steroid Sparing Device — New York, New York
Explore by condition: All CTCL clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.